UniProt Q9P0L2 · PDB · AlphaFold · Substrate: CHKtide · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Midostaurin | 93.4% | 6.6% | 78.64 | 0.500 |
| 2 | Brigatinib | 82.5% | 17.5% | 82.96 | 0.513 |
| 3 | Defactinib | 64.2% | 35.8% | 92.68 | 0.450 |
| 4 | Axitinib | 58.6% | 41.4% | 93.23 | 0.688 |
| 5 | Baricitinib | 54.4% | 45.6% | 97.99 | 0.616 |
| 6 | Repotrectinib | 48.8% | 51.2% | 84.21 | 0.608 |
| 7 | Sunitinib | 44.6% | 55.4% | 91.73 | 0.524 |
| 8 | Pemigatinib | 40.7% | 59.3% | 98.23 | 0.718 |
| 9 | Crizotinib | 30.7% | 69.3% | 91.39 | 0.581 |
| 10 | Upadacitinib | 29.6% | 70.4% | 97.98 | 0.663 |
| 11 | Ruxolitinib | 26.7% | 73.3% | 98.25 | 0.592 |
| 12 | Neratinib | 19.9% | 80.1% | 93.18 | 0.597 |
| 13 | Pacritinib | 15.9% | 84.1% | 88.64 | 0.452 |
| 14 | Bosutinib | 15.5% | 84.5% | 87.22 | 0.555 |
| 15 | Canertinib | 13.3% | 86.7% | 96.49 | 0.671 |
| 16 | Capmatinib | 11.8% | 88.2% | 99.75 | 0.582 |
| 17 | Nintedanib | 11.4% | 88.6% | 90.23 | 0.608 |
| 18 | Rabusertib | 9.9% | 90.1% | 98.74 | 0.687 |
| 19 | Fostamatinib | 9.7% | 90.3% | 96.74 | 0.613 |
| 20 | Fedratinib | 8.9% | 91.1% | 96.21 | 0.576 |
Paralog block
MARK1, MARK2_PAR_1BA, MARK3, MARK4
EMT expression
- Mesenchymal log2(TPM+1): 1.01
- Epithelial log2(TPM+1): 1.63
- Fold change: -0.62
- Status: No significant change
Selectivity landscape vs inhibition on MARK1
Each point is one of the 92 approved drugs; color = inhibition % on MARK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…